Pioneering Regenerative Medicine Drug Therapies for Heart Disease

Heart Disease is the Leading Cause of Death Worldwide

Revidia Therapeutics is developing first-in-class drug therapies to repair and regenerate damaged heart tissue, offering new hope for patients with heart failure and other serious cardiac conditions.

Explore our innovative approach to cardiac regenerative medicine and learn how Revidia is addressing the fatal cardiac complications of Duchenne muscular dystrophy (DMD) and other types of heart disease and injury.

Revidia Therapeutics is Addressing the Main Cause of Mortality in DMD Patients – Heart Failure

MSI-1436 Holds Promise for Treating Heart Failure in DMD Patients and in Patients with other Life-Threatening Forms of Heart Injury

Addressing the Unmet Need in DMD Cardiomyopathy: MSI-1436 Development Timeline

A Different Approach, a Shared Goal: Improving the Lives of Heart Disease Patients

Revidia Therapeutics was founded to address the limitations of current cardiac regenerative medicine R&D.  Our paradigm shifting approach utilizes novel animal models to identify drug candidates with the ability to reactivate the innate regenerative capacity in damaged heart muscle.

We are driven by a commitment to scientific excellence, patient-centricity, and a belief in the power of innovation to transform lives.

Leadership Team

Kevin Strange, Ph.D.

Founder and Chief Executive Officer

Dr. Kevin Strange is an internationally recognized biomedical scientist, and entrepreneur. His research has been funded for more than 35 years by the National Institutes of Health, Department of Defense, and private foundations, and has been published in leading scientific journals including Science, PNAS, Neuron and Cell.  He is the recipient of numerous awards including the John C. Parker Endowed Chair and Pittinger Award for Excellence in Basic Research.  Dr. Strange earrned his Ph.D. from the University of British Columbia and conducted postdoctoral training in membrane and renal physiology at the National Institutes of Health.

After a distinguished scientific and leadership career at Harvard Medical School and Vanderbilt University School of Medicine, Dr. Strange became the first president of the MDI Biological Laboratory in 2009 where he established the Kathryn W. Davis Center for Regenerative Biology and Medicine.  The Davis Center was highlighted twice in the U.S. Congressional Record for its scientific accomplishments including the discovery of regenerative medicine drug candidates.  Dr. Strange founded Revidia Therapeutics in 2013 to develop MSI-1436 and other small molecule regenerative medicine therapeutics.

Michael Christensen, Ph.D.

Executive Vice President for Business Development

Dr. Michael Christensen has spent more than 20 years in the pharmaceutical industry and has helped bring more than a dozen drugs to market, including Ozempic^® (semaglutide), Tresiba^® (insulin degludec), Isturisa^® (osilodrostat), Recorlev^® (levoketoconazole), Micardis^® (telmisartan), and other drug products in the cardiometabolic space.  He earned his Ph.D. in pharmacology at Vanderbilt University and completed his postdoctoral training in immunology at the Genomics Institute of the Novartis Research Foundation (GNF).

Dr. Christensen’s experience at both large and small pharmaceutical companies includes clinical trial development and execution, regulatory and medical affairs, and business and marketing operations. He has worked extensively with regulatory bodies including the FDA, Medicare/Medicaid and Veterans Affairs.  In addition to his role at Revidia, Dr. Christensen is also the President and Chairman of the Board of Directors at Prometheus Cardiology and Rare Disease, Inc.

Michael Stein, M.D., F.A.C.C.

Vice President for Clinical Development

Dr. Michael Stein is a cardiologist, well-published clinician scientist and experienced drug developer.  He previously served as Vice President and Head of Study Medical Experts for Bayer Pharmaceuticals; Senior Director and Project Head of Clinical Development for Ikaria Biopharmaceuticals; Senior Director for Clinical Development at Novo Nordisk Pharmaceuticals; Senior Medical Director for Daiichi Sankyo; and Director of Cardiovascular Clinical Development at AstraZeneca. Dr. Stein has played key roles in bringing diverse therapies drugs to clinical practice including AZD6140/ticagrelor/Brilinta^® and Prasugrel/Effient^® for reducing clot formation in heart attack and stroke patients; Anti-TFPI antibody for improving coagulation in hemophilia patients; and IK5001 hydrogel for reduction or elimination of ventricular remodeling following large myocardial infarction. 

Dr. Stein received his M.D. from the University of Illinois and fellowship training in cardiology and interventional cardiology at the University of Iowa.  He has served on the medical faculties at the of Wisconsin College of Medicine and Emory University College of Medicine.  His basic research efforts have focused on diverse aspects of cardiovascular physiology and pathophysiology. 

Medical Advisory Board

Linda Cripe, M.D.

Dr. Linda Cripe is professor of pediatrics and a pediatric cardiologist for The Heart Center at Nationwide Children’s Hospital.  She is also a member of the physician team for the Neuromuscular Disorders section of the Nationwide Neurosciences Center. Dr. Cripe’s clinical interests focus on non-invasive cardiac imaging specifically echocardiography as well as on the care and treatment of cardiomyopathy associated with neuromuscular disease, such as Duchenne muscular dystrophy (DMD). She was a member of the Centers for Disease Control National Steering Committee Duchenne Muscular Dystrophy Standards of Care and has been an invited lecturer nationally and internationally on cardiomyopathy related to DMD. Dr. Cripe is currently a member of the Scientific Advisory Board for Parent Project Muscular Dystrophy (PPMD).

Dr. Jennifer Monti is a board-certified cardiologist subspecialized in cardiogenetic disorders of young adults. She received her undergraduate degree in biochemistry from Harvard College and degrees in medicine and public health from Case Western Reserve University, with residency and fellowship training at Johns Hopkins and the University of Pennsylvania. Dr. Monti’s research and clinical expertise include heart failure, vascular biology, sudden cardiac death, and public-private investments in emerging technologies and business development.  She is the founder and CEO of Shock Analytics, on the health team @Meta, and an entrepreneur in residence at Northeastern University’s Roux Institute.